MEDIGUS LTD - SPON ADR (MDGS) Fundamental Analysis & Valuation

NASDAQ:MDGS • US58471G4091

Current stock price

2.36 USD
+0.18 (+8.28%)
At close:
2.6 USD
+0.24 (+10.17%)
After Hours:

This MDGS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MDGS Profitability Analysis

1.1 Basic Checks

  • MDGS had negative earnings in the past year.
  • In the past year MDGS has reported a negative cash flow from operations.
MDGS Yearly Net Income VS EBIT VS OCF VS FCFMDGS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 5M -5M -10M

1.2 Ratios

  • MDGS has a Return On Assets (-15.49%) which is comparable to the rest of the industry.
  • Looking at the Return On Equity, with a value of -41.78%, MDGS is in line with its industry, outperforming 51.28% of the companies in the same industry.
Industry RankSector Rank
ROA -15.49%
ROE -41.78%
ROIC N/A
ROA(3y)-6.62%
ROA(5y)-36.99%
ROE(3y)-13.71%
ROE(5y)-66.82%
ROIC(3y)N/A
ROIC(5y)N/A
MDGS Yearly ROA, ROE, ROICMDGS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300

1.3 Margins

  • Looking at the Gross Margin, with a value of 14.92%, MDGS is doing worse than 81.03% of the companies in the same industry.
  • MDGS's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for MDGS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-21.6%
MDGS Yearly Profit, Operating, Gross MarginsMDGS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. MDGS Health Analysis

2.1 Basic Checks

  • MDGS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for MDGS has been reduced compared to 1 year ago.
  • MDGS has a worse debt/assets ratio than last year.
MDGS Yearly Shares OutstandingMDGS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M 4M 5M
MDGS Yearly Total Debt VS Total AssetsMDGS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -0.19, we must say that MDGS is in the distress zone and has some risk of bankruptcy.
  • MDGS has a Altman-Z score (-0.19) which is in line with its industry peers.
  • A Debt/Equity ratio of 0.11 indicates that MDGS is not too dependend on debt financing.
  • The Debt to Equity ratio of MDGS (0.11) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z -0.19
ROIC/WACCN/A
WACC7.41%
MDGS Yearly LT Debt VS Equity VS FCFMDGS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 10M -10M 20M 30M 40M

2.3 Liquidity

  • MDGS has a Current Ratio of 1.30. This is a normal value and indicates that MDGS is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.30, MDGS is doing worse than 87.69% of the companies in the same industry.
  • A Quick Ratio of 1.23 indicates that MDGS should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.23, MDGS is not doing good in the industry: 75.90% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.3
Quick Ratio 1.23
MDGS Yearly Current Assets VS Current LiabilitesMDGS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. MDGS Growth Analysis

3.1 Past

  • The earnings per share for MDGS have decreased strongly by -116.00% in the last year.
  • MDGS shows a strong growth in Revenue. In the last year, the Revenue has grown by 158.35%.
  • Measured over the past years, MDGS shows a very strong growth in Revenue. The Revenue has been growing by 187.58% on average per year.
EPS 1Y (TTM)-116%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-65%
Revenue 1Y (TTM)158.35%
Revenue growth 3Y598.11%
Revenue growth 5Y187.58%
Sales Q2Q%52.72%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y25.58%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year25.68%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MDGS Yearly Revenue VS EstimatesMDGS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
MDGS Yearly EPS VS EstimatesMDGS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2020 2021 2022 2023 -5 -10

More info and screens

Find the best growth stocksShow best growing peers

0

4. MDGS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MDGS. In the last year negative earnings were reported.
  • Also next year MDGS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDGS Price Earnings VS Forward Price EarningsMDGS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDGS Per share dataMDGS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. MDGS Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 29.82%, MDGS is a good candidate for dividend investing.
  • The stock price of MDGS dropped by -30.59% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
  • MDGS's Dividend Yield is rather good when compared to the industry average which is at 0.26. MDGS pays more dividend than 100.00% of the companies in the same industry.
  • MDGS's Dividend Yield is rather good when compared to the S&P500 average which is at 1.80.
Industry RankSector Rank
Dividend Yield 29.82%

5.2 History

  • MDGS is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
MDGS Yearly Dividends per shareMDGS Yearly Dividends per shareYearly Dividends per share 2022 1 2 3 4

5.3 Sustainability

  • The earnings of MDGS are negative and hence is the payout ratio. MDGS will probably not be able to sustain this dividend level.
DP-31.57%
EPS Next 2YN/A
EPS Next 3YN/A
MDGS Yearly Income VS Free CF VS DividendMDGS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 0 5M -5M -10M

More info and screens

Find the best dividend stocksShow peers with best dividend

MDGS Fundamentals: All Metrics, Ratios and Statistics

MEDIGUS LTD - SPON ADR

NASDAQ:MDGS (4/17/2024, 8:12:04 PM)

After market: 2.6 +0.24 (+10.17%)

2.36

+0.18 (+8.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Industry StrengthN/A
Industry GrowthN/A
Earnings (Last)09-23
Earnings (Next)N/A
Inst Owners0%
Inst Owner Change-99.92%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap4.47M
Revenue(TTM)110.29M
Net Income(TTM)-13.27M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 29.82%
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP-31.57%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.04
P/FCF N/A
P/OCF N/A
P/B 0.14
P/tB 6.13
EV/EBITDA N/A
EPS(TTM)-6.98
EYN/A
EPS(NY)-4.9
Fwd EYN/A
FCF(TTM)-4.25
FCFYN/A
OCF(TTM)-3.33
OCFYN/A
SpS58.21
BVpS16.77
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -15.49%
ROE -41.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.92%
FCFM N/A
ROA(3y)-6.62%
ROA(5y)-36.99%
ROE(3y)-13.71%
ROE(5y)-66.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-21.6%
F-Score3
Asset Turnover1.29
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 51.17%
Cap/Sales 1.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.3
Quick Ratio 1.23
Altman-Z -0.19
F-Score3
WACC7.41%
ROIC/WACCN/A
Cap/Depr(3y)598.88%
Cap/Depr(5y)379.57%
Cap/Sales(3y)37.08%
Cap/Sales(5y)27.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-116%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-65%
EPS Next Y25.58%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)158.35%
Revenue growth 3Y598.11%
Revenue growth 5Y187.58%
Sales Q2Q%52.72%
Revenue Next Year25.68%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-44.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y22.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.17%
OCF growth 3YN/A
OCF growth 5YN/A

MEDIGUS LTD - SPON ADR / MDGS Fundamental Analysis FAQ

What is the fundamental rating for MDGS stock?

ChartMill assigns a fundamental rating of 2 / 10 to MDGS.


Can you provide the valuation status for MEDIGUS LTD - SPON ADR?

ChartMill assigns a valuation rating of 0 / 10 to MEDIGUS LTD - SPON ADR (MDGS). This can be considered as Overvalued.


Can you provide the profitability details for MEDIGUS LTD - SPON ADR?

MEDIGUS LTD - SPON ADR (MDGS) has a profitability rating of 1 / 10.


Can you provide the financial health for MDGS stock?

The financial health rating of MEDIGUS LTD - SPON ADR (MDGS) is 2 / 10.


Can you provide the expected EPS growth for MDGS stock?

The Earnings per Share (EPS) of MEDIGUS LTD - SPON ADR (MDGS) is expected to grow by 25.58% in the next year.